Marqibo Approval History
- FDA approved: Yes (First approved August 9th, 2012)
- Brand name: Marqibo
- Generic name: vincristine sulfate liposomes
- Dosage form: Injection
- Previous name: Onco TCS
- Company: Talon Therapeutics Inc.
- Treatment for: Acute Lymphoblastic Leukemia
Marqibo (vincristine sulfate liposome injection) is a vinca alkaloid indicated for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).
Development History and FDA Approval Process for Marqibo
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.